Multiple Sclerosis

Latest News

Cognitive Fatigue and Circadian Cortisol Regulation in Multiple Sclerosis

Publish Date October 19, 2020

Patients with multiple sclerosis had higher cortisol levels than healthy controls, with slightly higher levels in those with multiple sclerosis without than with fatigue.

Specific Factors Tied to Unemployment With MS Diagnosis

Publish Date October 14, 2020

Disease course, fatigue, self-efficacy, and diet and exercise are major determinants of unemployment for patients with MS.

Assessing Need for Walking Support Helps Identify Mobility Capabilities in MS

Publish Date October 6, 2020

12-item Multiple Sclerosis Walking Scale items offer insight into mobility of mildly and moderately-severely disabled patients with multiple sclerosis.

Immunotherapy Slows Disability in Patients With Active Relapses During Secondary Progressive MS

Publish Date September 28, 2020

In patients with active relapses in secondary progressive multiple sclerosis, disease-modifying therapies improved disability outcomes.

Early, Continuous Ocrelizumab Therapy Reduces Relapsing MS Progression

Publish Date September 25, 2020

Early, continuous ocrelizumab was related to a sustained reduction of relapsing MS progression compared with patients who switched from IFN β-1a.

Pregnancy May Delay Onset of Multiple Sclerosis Symptoms

Publish Date September 24, 2020

The researchers found that the mean age at CIS onset was 31.5 years. Before CIS onset, 46 percent of women had at least one pregnancy and 43 percent had at least one childbirth.

Ponesimod Shown Promising for MRI Outcomes in Relapsing MS

Publish Date September 18, 2020

Compared to teriflunomide, ponesimod showed benefit for magnetic resonance imaging (MRI) outcomes in relapsing multiple sclerosis.

Extended-Release Amantadine Improves Walking Speed in Patients With MS

Publish Date September 18, 2020

ADS-5102, the extended release capsule form of amantadine, may clinically benefit walking speed in patients with multiple sclerosis.

Amiloride, Fluoxetine, Riluzole Do Not Reduce Atrophy Rates in Secondary Progressive MS

Publish Date September 18, 2020

In secondary progressive multiple sclerosis, amiloride, fluoxetine, and rizuole treatments do not translate into long-term reduction in atrophy rates.

CSF UCH-L1 Biomarker Predictive of Long-Term Disease Progression in MS

Publish Date September 18, 2020

Baseline levels of ubiquitin C-terminal hydrolase L1 in cerebral spinal fluid may be predictive of long term multiple sclerosis progression.